KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2026)

Aurinia Pharmaceuticals filings provide 3 years of Finished Goods readings, the most recent being $379000.0 for Q4 2025.

  • On a quarterly basis, Finished Goods fell 58.03% to $379000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $379000.0, a 58.03% decrease, with the full-year FY2025 number at $379000.0, down 58.03% from a year prior.
  • Finished Goods hit $379000.0 in Q4 2025 for Aurinia Pharmaceuticals, down from $1.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.7 million in Q1 2025 to a low of $379000.0 in Q4 2025.
  • Median Finished Goods over the past 3 years was $1.1 million (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Finished Goods: skyrocketed 54.89% in 2024 and later plummeted 58.03% in 2025.
  • Aurinia Pharmaceuticals' Finished Goods stood at $583000.0 in 2023, then skyrocketed by 54.89% to $903000.0 in 2024, then plummeted by 58.03% to $379000.0 in 2025.
  • The last three reported values for Finished Goods were $379000.0 (Q4 2025), $1.4 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.